Vasoactive intestinal peptide (VIP) receptor modulators represent a promising therapeutic approach for neurodegenerative diseases. VIP signals through VPAC1 and VPAC2 receptors, G protein-coupled receptors (GPCRs) of the secretin family, to exert neuroprotective, anti-inflammatory, and immunomodulatory effects[1]. This page covers drug candidates, clinical development status, and delivery strategies for VIP-based therapies in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and related disorders.
VIP receptor activation produces multiple neuroprotective effects:
VIP-based therapies address core AD pathology through multiple mechanisms[3][4]:
VIP offers dopaminergic neuroprotection through[5][6][7]:
VIP provides motor neuron protection in ALS models[8]:
VIP shows promise in HD models[9]:
| Drug | Target | Stage | Indication | Key Features |
|---|---|---|---|---|
| Aviptadil (RL-001) | VPAC1/VPAC2 | Phase 2 | AD, PD | Synthetic VIP analog; safe in humans |
| Ro 25-1392 | VPAC2 | Preclinical | AD | Selective VPAC2 agonist; enhances memory |
| BAY 55-9837 | VPAC1/VPAC2 | Preclinical | PD | Mixed agonist; dopaminergic protection |
Aviptadil is a synthetic 28-amino acid VIP analog that has undergone clinical testing:
VIP-based therapeutics face significant delivery challenges[10][11]:
VIP/VPAC modulators share similarities with GLP-1 receptor agonists:
Key differences:
VIP-based therapies have shown favorable safety profiles:
Harmar et al. VPAC receptors. Pharmacological Reviews. 2012. ↩︎
Gozes et al. Vasoactive intestinal peptide: neuroprotective drug?. Journal of Molecular Neuroscience. 2009. ↩︎
Brenneman et al. VIP in Alzheimer's disease. Annals of the New York Academy of Sciences. 2003. ↩︎
Pass et al. VIP and amyloid. Journal of Alzheimer's Disease. 2006. ↩︎
Offen et al. VIP in Parkinson's disease models. Journal of Neural Transmission. 2000. ↩︎
Samaranch et al. VIP and alpha-synuclein. Journal of Parkinson's Disease. 2014. ↩︎
Kong et al. VIP neuroinflammation. Journal of Neuroinflammation. 2012. ↩︎
Nguyen et al. VIP in ALS models. Experimental Neurology. 2001. ↩︎
Maqbool et al. VIP in Huntington's disease. Journal of Huntington's Disease. 2013. ↩︎
Bundgaard et al. Peptide delivery to the brain. Advanced Drug Delivery Reviews. 2012. ↩︎
Kumar et al. VIP delivery strategies. Neurobiology of Disease. 2015. ↩︎